Good Times Ahead for Cell Therapy?
Pathfinder Going Public Via SyntheMed Reverse Merger
By Tom Wall
Monday, December 27, 2010
Believing that it's a good time to access capital and make a move in the cell therapy space, Pathfinder LLC, of Cambridge, Mass., will become a public company via a reverse merger with biomaterials company SyntheMed Inc., of Iselin, N.J.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.